European Journal of Surgical Oncology
Volume 36, Issue 5 , Pages 431-438 , May 2010

Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer

  • N.-P. Tang

      Affiliations

    • National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai institute of pharmaceutical industry, 199 Guoshoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, PR China
    • Corresponding Author InformationCorresponding author. Tel.: +86 21 50800333; fax: +86 21 50801259.
    • ,
  • Y.-M. Wu

      Affiliations

    • Department of General Surgery, People's Hospital of Liyang City, Liyang, Jiangsu Province, PR China
    • ,
  • B. Wang

      Affiliations

    • Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu Province, PR China
    • ,
  • J. Ma

      Affiliations

    • National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai institute of pharmaceutical industry, 199 Guoshoujing Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203, PR China

,Accepted 22 March 2010.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  3. Selby JV, Friedman GD, Quesenberry CP, Weiss NS. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med. 1992;326:653–657
  4. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–932
  5. Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med. 2002;137:603–612
  6. Zhu H, Yang L, Zhou B, Yu R, Tang N, Wang B. Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case-control study. Carcinogenesis. 2006;27:2491–2496
  7. Tomlinson IP, Webb E, Carvajal-Carmona L, et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet. 2008;40:623–630
  8. Tenesa A, Farrington SM, Prendergast JG, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet. 2008;40:631–637
  9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53
  10. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  11. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  13. Langerod A, Bukholm IR, Bregard A, et al. The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev. 2002;11:1684–1688
  14. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML. p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res. 2004;10:5845–5849
  15. Lung FW, Lee TM, Shu BC, Chang FH. p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol. 2004;130:728–732
  16. Talseth BA, Meldrum C, Suchy J, Kurzawski G, Lubinski J, Scott RJ. Age of diagnosis of colorectal cancer in HNPCC patients is more complex than that predicted by R72P polymorphism in TP53. Int J Cancer. 2006;118:2479–2484
  17. Khan SA, Idrees K, Forslund A, et al. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. J Surg Oncol. 2008;97:621–625
  18. Katkoori VR, Jia X, Shanmugam C, et al. Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res. 2009;15:2406–2416
  19. Sotamaa K, Liyanarachchi S, Mecklin JP, et al. p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res. 2005;11:6840–6844
  20. Mammano E, Belluco C, Bonafe M, et al. Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol. 2009;35:415–419
  21. Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G. Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet. 1991;86:369–370
  22. Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S. Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis. 1993;14:1085–1089
  23. Sjalander A, Birgander R, Athlin L, et al. P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 1995;16:1461–1464
  24. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis. 1996;17:261–264
  25. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol. 2001;109:25–34
  26. Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–85
  27. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 2004;23:1954–1956
  28. Schneider-Stock R, Boltze C, Peters B, et al. Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia. 2004;6:529–535
  29. Kruger S, Bier A, Engel C, et al. The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet. 2005;42:769–773
  30. Perez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol. 2006;12:1426–1429
  31. Perfumo C, Bonelli L, Menichini P, et al. Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion. 2006;74:228–235
  32. Koushik A, Tranah GJ, Ma J, et al. p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer. 2006;119:1863–1868
  33. Lima JM, Serafim PV, Silva ID, Forones NM. Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer. Arq Gastroenterol. 2006;43:8–13
  34. Zhu ZZ, Wang AZ, Jia HR, et al. Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 2007;37:385–390
  35. Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H, Chang-Claude J. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?. Pharmacogenet Genomics. 2007;17:639–645
  36. Kruger S, Engel C, Bier A, et al. The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer Lett. 2007;252:55–64
  37. Dakouras A, Nikiteas N, Papadakis E, et al. P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res. 2008;28:1039–1043
  38. Csejtei A, Tibold A, Varga Z, et al. GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res. 2008;28:1917–1922
  39. Cao Z, Song JH, Park YK, et al. The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma. 2009;56:114–118
  40. Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A. p 53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer. 2010;47:31–34
  41. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196–199
  42. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19:1092–1100
  43. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365
  44. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 2000;25:47–54
  45. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998;393:229–234
  46. Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57:1083–1093
  47. Thomas DC, Witte JS. Point: population stratification: a problem for case-control studies of candidate-gene associations?. Cancer Epidemiol Biomarkers Prev. 2002;11:505–512

PII: S0748-7983(10)00066-1

doi: 10.1016/j.ejso.2010.03.010

European Journal of Surgical Oncology
Volume 36, Issue 5 , Pages 431-438 , May 2010

Article Tools

* Image Usage & Resolution